Condition: Cardiac Toxicity · Early-stage Breast Cancer · Sponsor: Rutgers, The State University of New Jersey
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
This description comes directly from the study's public registry record.
Mridula George, MD · 732-235-9081 · mridula@cinj.rutgers.edu
Coral Omene, MD · 732-235-3374 · co273@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| Trinitas Hospital and Comprehensive Cancer Center | Elizabeth, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton, New Jersey, United States | Recruiting |
| RWJBarnabas Health - - Jersey City Medical Medical | Jersey City, New Jersey, United States | Recruiting |
| Monmouth Medical Center Southern Campus | Lakewood, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Monmouth Medical Center | Long Branch, New Jersey, United States | Recruiting |
| Monmouth Community Medical | Long Branch, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick, New Jersey, United States | Not Yet Recruiting |
| RWJBarnabas Health - Newark Beth Israel Medical Center | Newark, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | Somerset, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05559164